Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.90 |
---|---|
High | 12.90 |
Low | 12.50 |
Bid | 13.50 |
Offer | 14.00 |
Previous close | 13.60 |
Average volume | 4.00 |
---|---|
Shares outstanding | 69.16m |
Free float | 66.36m |
P/E (TTM) | -- |
Market cap | 946.15m USD |
EPS (TTM) | -1.51 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 14:29 GMT.
More ▼
- Zymeworks Announces Participation in Upcoming Investor Conferences
- FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
- Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
- Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
- Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
- Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
- Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
- Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
- Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
More ▼